Teva, Allergan win U.S. antitrust approval for generics deal

WASHINGTON (Reuters) – Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

Original post: 
Teva, Allergan win U.S. antitrust approval for generics deal